Core Insights - The company, established in June 2007 and listed on the Shanghai Stock Exchange in March 2022, is a leading domestic RNA precision diagnostics enterprise with a focus on molecular diagnostic reagents and instruments, leveraging SDA technology for competitive advantage [1] Financial Performance - For Q3 2025, the company reported revenue of 119 million yuan, ranking 38th in the industry, significantly lower than the top competitor's revenue of 3.428 billion yuan and the second competitor's 3.127 billion yuan, as well as below the industry average of 708 million yuan and median of 330 million yuan [2] - The main business composition includes reagent sales at 73.15 million yuan (90.04%), instrument sales at 6.89 million yuan (8.49%), and testing services at 1.19 million yuan (1.47%) [2] - The net profit for the same period was 7.01 million yuan, ranking 23rd in the industry, again trailing behind the leading competitor's net profit of 1.588 billion yuan and the second competitor's 1.205 billion yuan, as well as below the industry average of 110 million yuan and median of 26.19 million yuan [2] Financial Ratios - The company's debt-to-asset ratio for Q3 2025 was 7.25%, a decrease from 7.76% in the previous year, and significantly lower than the industry average of 18.29%, indicating lower debt pressure [3] - The gross profit margin for Q3 2025 was 77.75%, down from 80.39% year-on-year, but still well above the industry average of 56.20%, reflecting strong profitability [3] Executive Compensation - The chairman, Ju Jinliang, received a salary of 2.0472 million yuan in 2024, an increase of 54,000 yuan from 2023 [4] - The general manager, Yu Minghui, earned 1.0415 million yuan in 2024, a decrease of 684,000 yuan from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 7.73% to 3,765, with an average holding of 10,600 circulating A-shares, up 17.83% from the previous period [5]

Core Insights - Mingde Biological is a leading company in the in vitro diagnostic field in China, focusing on POCT technology and core technologies such as whole blood chemiluminescence [1] Financial Performance - For Q3 2025, Mingde Biological reported revenue of 227 million yuan, ranking 31st among 39 companies in the industry, with the industry leader New Industries generating 3.428 billion yuan [2] - The company's net profit for the same period was -12.4461 million yuan, placing it 29th in the industry, while the top performer, Ji'an Medical, reported a net profit of 1.588 billion yuan [2] Profitability and Debt Ratios - As of Q3 2025, Mingde Biological's debt-to-asset ratio was 6.13%, significantly lower than the industry average of 18.29%, indicating strong debt repayment capability [3] - The company's gross profit margin was 32.31%, down from 51.79% year-on-year and below the industry average of 56.20%, suggesting a need for improvement in profitability [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.55% to 23,200, while the average number of shares held per shareholder increased by 0.56% to 6,741.17 [5] - Notable shareholders include Guangfa Value Core Mixed A, holding 2.8462 million shares, and new entrants like Rongtong Health Industry Flexible Allocation Mixed A/B [5] Leadership Compensation - The chairman and general manager, Chen Lili, received a salary of 600,000 yuan in 2024, unchanged from 2023 [4]

证券研究报告 安图生物 (603658 CH) 静待政策影响消化后业绩改善 | 华泰研究 | | | 季报点评 | 投资评级(维持): | 买入 | | --- | --- | --- | --- | --- | --- | | 2025 年 | 10 月 | 30 日│中国内地 | 医疗器械 | 目标价(人民币): | 45.19 | 公司 9M25 收入/归母净利润/扣非归母净利润分别为 31.27/8.60/8.15 亿元， 同比-7.5%/-10.1%/-12.4%；3Q25 收入/归母净利润/扣非归母净利润 10.67/2.89/2.69 亿元，同比-9.0%/-14.3%/-18.8%。3Q25 业绩增速承压， 我们看好后续政策影响消化后业绩恢复增长，维持买入评级。 海外收入保持快速增长，磁微粒发光试剂收入承压 公司海外业务持续拓展，我们估计 9M25 海外收入保持快速增长。磁微粒化 学发光试剂受集采及 DRGs 等政策影响，收入承压，我们预期 2026 年相关 影响基本消化，恢复增长。我们估计磁微粒化学发光仪 2025 年全年装机超 1000 台。公司持续发力流水线业务，进口线体 A1/B1 以 ...

Core Viewpoint - Antu Biology is a leading company in the in vitro diagnostics sector in China, with a comprehensive product range and strong market position, ranking second in revenue and third in net profit among industry peers in Q3 2025 [1][2]. Group 1: Business Performance - In Q3 2025, Antu Biology reported revenue of 3.127 billion yuan, ranking second among 39 companies in the industry, with the top company generating 3.428 billion yuan [2]. - The revenue composition includes 1.785 billion yuan from reagents (86.63%), 226 million yuan from instruments (10.99%), and 28.9 million yuan from other sources (1.40%) [2]. - The net profit for the same period was 873 million yuan, placing the company third in the industry, with the leading company achieving 1.588 billion yuan [2]. Group 2: Financial Ratios - As of Q3 2025, Antu Biology's debt-to-asset ratio was 24.57%, higher than the industry average of 18.29%, but down from 25.49% in the previous year [3]. - The gross profit margin stood at 64.83%, exceeding the industry average of 56.20%, although it slightly decreased from 65.86% year-on-year [3]. Group 3: Management and Shareholder Information - The chairman, Miao Yongjun, received a salary of 1.06 million yuan in both 2024 and 2023, indicating stability in compensation [4]. - As of September 30, 2025, the number of A-share shareholders decreased by 0.58% to 34,000, while the average number of shares held per shareholder increased by 0.58% to 16,800 [5]. Group 4: Market Outlook and Innovations - The company is actively expanding its overseas market presence, with overseas revenue reaching 157 million yuan in the first half of 2025, a year-on-year increase of 19.8% [5]. - Antu Biology plans to launch new products, including a liquid chromatography-tandem mass spectrometry series in 2025, and has made significant progress in the NGS sector through its subsidiary [6]. - The company is expected to see a gradual recovery in performance, with projected net profits of 1.108 billion yuan, 1.340 billion yuan, and 1.617 billion yuan for 2025, 2026, and 2027, respectively [6].

Core Insights - Anxu Bio, established in July 2008 and listed on the Shanghai Stock Exchange in November 2021, is a leading company in the domestic POCT reagent field, with a full industry chain advantage and high product quality and technology level [1] Financial Performance - For Q3 2025, Anxu Bio reported revenue of 325 million yuan, ranking 21st out of 39 in the industry, significantly lower than the top competitor's revenue of 3.428 billion yuan and the second competitor's 3.127 billion yuan, as well as below the industry average of 708 million yuan and median of 330 million yuan [2] - The company's net profit for the same period was 64.31 million yuan, ranking 14th in the industry, again far below the top competitor's net profit of 1.588 billion yuan and the second competitor's 1.205 billion yuan, but higher than the industry median of 26.19 million yuan and lower than the industry average of 110 million yuan [2] Financial Ratios - Anxu Bio's debt-to-asset ratio for Q3 2025 was 8.59%, down from 11.21% in the previous year and below the industry average of 18.29%, indicating strong solvency [3] - The gross profit margin for the same period was 40.82%, a decrease from 42.11% year-on-year and lower than the industry average of 56.20%, suggesting a need for improvement in profitability [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 1.10% to 6,090, while the average number of circulating A-shares held per shareholder decreased by 1.08% to 20,900 [5] - Among the top ten circulating shareholders, Guangfa Value Core Mixed A ranked fifth with 3.5645 million shares, an increase of 549,800 shares from the previous period, while the eighth largest shareholder,招商景气优选股票A, held 600,000 shares, unchanged from the previous period [5]

Core Viewpoint - Kemei Diagnostics, established in 2007 and listed in 2021, specializes in clinical immunochemistry and has unique technological advantages in the in vitro diagnostics sector [1] Group 1: Business Performance - In Q3 2025, Kemei Diagnostics reported revenue of 261 million yuan, ranking 25th in the industry, significantly lower than the top competitor's revenue of 3.428 billion yuan [2] - The main business revenue is primarily from LiCA series products, contributing 154 million yuan, accounting for 93.42% of total revenue [2] - The net profit for the same period was 41.56 million yuan, ranking 18th in the industry, but higher than the industry median of 26.19 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, Kemei Diagnostics had a debt-to-asset ratio of 20.50%, which is higher than the industry average of 18.29% [3] - The gross profit margin for the same period was 68.02%, exceeding the industry average of 56.20% [3] Group 3: Executive Compensation - The chairman and general manager, Li Lin, received a salary of 962,200 yuan in 2024, a decrease of 399,400 yuan from the previous year [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.60% to 10,400 [5] - The average number of circulating A-shares held per shareholder increased by 0.61% to 38,600 [5]

证券代码：603658 证券简称：安图生物 公告编号：2025-074 郑州安图生物工程股份有限公司 关于公司及全资子公司获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）及全 资子公司郑州思昆生物工程有限公司（以下简称"思昆生物"）于近日收到国家 药品监督管理局、河南省药品监督管理局颁发的医疗器械注册证，具体如下： | 牛奶过敏原特异性 | 本产品用于体外定量检测人血清 | IgE | 豫械注准 | 抗体检测试剂盒（磁微 | 年 | 中牛奶过敏原特异性 | 抗体（f2 | 7 | 5 | IgE | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 20252400870 | 粒化学发光法） | sIgE）的含量。 | | | ...

Core Points - Antu Biology (603658) reported a financing net purchase of 2.09 million yuan on October 29, with a financing balance of 612 million yuan, indicating a continuous net purchase trend over the past three trading days totaling 10.62 million yuan [1][4] - The financing balance has shown an increase of 0.34% compared to the previous day, reflecting a positive trend in investor sentiment [4] Financing Summary - On October 29, the financing net purchase was 2.09 million yuan, with a financing balance of 612 million yuan, representing 2.77% of the circulating market value [2] - Over the last 20 trading days, there were 11 days with financing net purchases, indicating sustained interest from investors [1] - The financing balance has increased from 601 million yuan on October 24 to 612 million yuan on October 29, showing a consistent upward trend [4] Margin Trading Summary - On October 29, there were no net sell transactions in margin trading, with a remaining margin balance of 67,300 shares [3] - The margin trading balance was 2.60 million yuan on October 29, slightly up from 2.59 million yuan on October 28 [3] Overall Margin Balance - The total margin balance reached 614 million yuan on October 29, reflecting a daily increase of 209.86 thousand yuan [4] - The margin balance has shown fluctuations over the past few days, with a notable increase of 505.80 thousand yuan on October 28 [4]

Core Insights - Antu Biology (603658.SH) reported a decline in revenue and net profit for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company achieved total operating revenue of 3.127 billion yuan, representing a year-on-year decrease of 7.48% [1] - The net profit attributable to shareholders was 860 million yuan, down 10.11% year-on-year [1] - Basic earnings per share were reported at 1.5 yuan [1]

证券代码：603658 证券简称：安图生物 公告编号：2025-071 郑州安图生物工程股份有限公司 关于修订《公司章程》暨取消监事会、设置职工代表 董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）于 2025 年 10 月 28 日召开第五届董事会第八次会议、第五届监事会第七次会议，审议通 过了《关于修订<公司章程>暨取消监事会、设置职工代表董事的议案》。现将 相关情况公告如下： 一、修订《公司章程》暨取消监事会、设置职工代表董事： （1）根据《中华人民共和国公司法》（以下简称"《公司法》"）、中国 证监会《关于新〈公司法〉配套制度规则实施相关过渡期安排》《上市公司章程 指引（2025 年修订）》等法律法规及规范性文件的相关规定，结合公司实际情 况，公司拟不再设置监事会及监事岗位，《公司法》中原由监事会行使的规定职 权，将转由董事会审计委员会履行。《公司章程》经股东大会审议通过后，公司 《监事会议事规则》即行废止，公司监事会将停止履职，公司监事自动解任 ...